Two insulin biosimilars, Sanofi’s Truvelog Mix 30 rival to NovoMix (insulin aspart) and Baxter’s Inpremzia version of Actrapid (insulin human rDNA) have been granted positive opinions recommending pan-European marketing authorizations by the committee for medicinal products for human use within the European Medicines Agency.
Truvelog Mix 30 will be available as a 100U/ml suspension for injection while Inpremzia will be available as 1IU/ml solution for infusion
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?